Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of ceralifimod versus Avonex in relapsing-remitting multiple sclerosis
2013-002351-15Phase 3Terminated
- Sponsor
- Merck KGaA
- Start
- Feb 2014
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ceralifimod and interferon beta-1a in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by Merck KGaA. Primary endpoint: Proportion of subjects free of qualifying relapse. Started Feb 2014; status: terminated.
02
Drugs
ceralifimodinterferon beta-1a
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2013-002351-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002351-15.